NASDAQ
19.91USD
+0.02 (+0.10%)
We have scored 8 news catalysts on NeoGenomics, Inc. (NEO) over the past 12 months. The biggest single-day move next to one of them came Jun 6, 2026, when NEO closed −3.6%: “RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and Growth Strategy Ahead of Version 2 Launch”. Coverage across the window leans positive (average ticker sentiment +0.51). Most of the impact sits in earnings revision trend and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
511.6M
P/E
—
EPS
—
Beta
1.75
52W range
7.07-20.03
Day range
19.39–20.02
Open
20.02
Prev close
19.89
Volume
4.4M
Avg volume
2.4M
Dividend
0.00
IPO
2004-03-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about NeoGenomics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NEO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
